Skip to main content

Phase 2/3 Oncology Deal Benchmarks

Median Upfront
$470M
Range: $284M - $635M
Total Deal Value
$2.4B
Range: $1.7B - $3.1B
Royalty Rate
13.9% - 22.5%
Tiered up to 26.5%
Dev Milestones
$346M
Range: $250M - $446M
Model Your Deal

Market Analysis

Phase 2/3 oncology licensing deals carry a median total deal value of $2.4B, with upfront payments ranging from $284M to $635M. At this stage, deal structures are balanced between upfront and milestone payments, reflecting the proof-of-concept inflection. The recommended split allocates 20% to upfront and 80% to milestones.

The oncology landscape at the phase 2/3 stage is characterized by high competitive intensity with numerous active programs and a rapidly evolving standard of care. Development milestones average $346M, regulatory milestones contribute $731M, and commercial milestones reach $865M. ADCs, bispecifics, and radiopharmaceuticals continue to drive premium valuations across solid and hematologic tumors.

Royalty rates for phase 2/3 oncology deals range from 13.9% to 22.5% at the base tier, with high-tier escalation to 26.5%. Mid-stage royalties reflect the balance of de-risking achieved and remaining development investment.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the average upfront payment for phase 2/3 oncology deals?
Phase 2/3 oncology deals average $470M in upfront payments, ranging from $284M to $635M. The upfront allocation of 20% of total deal value reflects the clinical stage risk profile.
How are phase 2/3 oncology deal milestones structured?
Milestones account for approximately 80% of total deal value. Development milestones ($346M) represent the largest component, followed by commercial milestones ($865M) and regulatory milestones ($731M).
What royalty rates are typical for phase 2/3 oncology licensing?
Base royalty rates range from 13.9% to 22.5%, with tiered escalation to 17.9%-26.5% on peak sales. Rates are influenced by modality, competitive positioning, and territorial scope.
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Preclinical Oncology Deals

View

Phase 1 Oncology Deals

View

Phase 2/3 Neurology Deals

View

Phase 2/3 Immunology & Autoimmune Deals

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included